Nonparametric Bounds for Evaluating the Clinical Utility of Treatment Rules
Nonparametric Bounds for Evaluating the Clinical Utility of Treatment Rules
Evaluating the value of new clinical treatment rules based on patient characteristics is important but often complicated by hidden confounding factors in observational studies. Standard methods for estimating the average patient outcome if a new rule were universally adopted typically rely on strong, untestable assumptions about these hidden factors. This paper tackles this challenge by developing nonparametric bounds - a range of plausible values - for the expected outcome under a new rule, even with unobserved confounders present. We propose and investigate two main strategies for derivation of these bounds. We extend these techniques to incorporate Instrumental Variables (IVs), which can help narrow the bounds, and to directly estimate bounds on the difference in expected outcomes between the new rule and an existing clinical guideline. In simulation studies we compare the performance and width of bounds generated by the reduction and conditioning strategies in different scenarios. The methods are illustrated with a real-data example about prevention of peanut allergy in children. Our bounding frameworks provide robust tools for assessing the potential impact of new clinical treatment rules when unmeasured confounding is a concern.
Johannes Hruza、Erin Gabriel、Arvid Sjölander、Samir Bhatt、Michael Sachs
医学研究方法临床医学
Johannes Hruza,Erin Gabriel,Arvid Sjölander,Samir Bhatt,Michael Sachs.Nonparametric Bounds for Evaluating the Clinical Utility of Treatment Rules[EB/OL].(2025-08-20)[2025-09-02].https://arxiv.org/abs/2508.14653.点此复制
评论